Main menu

IDH-mutant Adult Gliomas Classification and Grading by Nanopore Technology


The 2021 WHO Classification of Tumors of the Central Nervous System adopted CDKN2A/B deletion marker into the revised grading criteria of IDH-mutant astrocytoma. The CDKN2A/B deletion in IDH-mutant astrocytoma was identified as independent molecular markers of the worst clinical outcomes. Currently, there is no standard assay to assess CDKN2A/B deletion, and current tests such as fluorescence in situ hybridization (FISH), array-based platforms require technical expertise and may not be readily available in routine laboratories. Here we demonstrated the nanopore-based copy number variation approach to identify deletions of CDKN2A/B for glioma diagnosis and grading within 4 hours.

Authors: Thidathip Wongsurawat

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

ナノポア技術

ナノポアの最新ニュースを購読 リソースと発表文献 Nanopore Communityとは

Oxford Nanoporeについて

ニュース 会社沿革 持続可能性 経営陣 メディアリソース & お問い合わせ先 投資家向け パートナー向け Oxford Nanopore社で働く 現在の募集状況 営業上の情報 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag